The DOI matches its Crossref record; 115 of the 115 references it cites were found in a registry or an index.
An Overview of Novel Adjuvants Designed for Improving Vaccine Efficacy
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Mahmoudi, S., & Keshavarz, H. (2017) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2016.1271686 · Cited by 9
RetractedPathogen Recognition and Innate Immunity
Akira, S., Uematsu, S., & Takeuchi, O. (2006) · Cell · doi:10.1016/j.cell.2006.02.015 · Cited by 11,952
Holmgren, J., & Czerkinsky, C. (2005) · Nature Medicine · doi:10.1038/nm1213 · Cited by 1,562
Key roles of adjuvants in modern vaccines
Reed, S. G., Orr, M. T., & Fox, C. B. (2013) · Nature Medicine · doi:10.1038/nm.3409 · Cited by 1,419
Crystal Structure of the TLR1-TLR2 Heterodimer Induced by Binding of a Tri-Acylated Lipopeptide
Jin, M. S., Kim, S. E., Heo, J. Y., Lee, M. E., Kim, H. M., Paik, S.-G., Lee, H., & Lee, J.-O. (2007) · Cell · doi:10.1016/j.cell.2007.09.008 · Cited by 1,344
Cutting Edge: Role of Toll-Like Receptor 1 in Mediating Immune Response to Microbial Lipoproteins
Takeuchi, O., Sato, S., Horiuchi, T., Hoshino, K., Takeda, K., Dong, Z., Modlin, R. L., & Akira, S. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.1.10 · Cited by 1,329
Discrimination of bacterial lipoproteins by Toll-like receptor 6
Takeuchi, O., Kawai, T., Mühlradt, P. F., Morr, M., Radolf, J. D., Zychlinsky, A., Takeda, K., & Akira, S. (2001) · International Immunology · doi:10.1093/intimm/13.7.933 · Cited by 1,232
Immunotherapeutic uses of CpG oligodeoxynucleotides
Klinman, D. M. (2004) · Nature Reviews Immunology · doi:10.1038/nri1329 · Cited by 1,012
Vaccine adjuvants: Current state and future trends
Petrovsky, N., & Aguilar, J. C. (2004) · Immunology & Cell Biology · doi:10.1111/j.0818-9641.2004.01272.x · Cited by 1,005
CpG Oligodeoxynucleotides Act as Adjuvants that Switch on T Helper 1 (Th1) Immunity
Chu, R. S., Targoni, O. S., Krieg, A. M., Lehmann, P. V., & Harding, C. V. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.10.1623 · Cited by 1,002
Bonifaz, L. C., Bonnyay, D. P., Charalambous, A., Darguste, D. I., Fujii, S.-I., Soares, H., Brimnes, M. K., Moltedo, B., Moran, T. M., & Steinman, R. M. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20032220 · Cited by 921
The interface between innate and adaptive immunity
Hoebe, K., Janssen, E., & Beutler, B. (2004) · Nature Immunology · doi:10.1038/ni1004-971 · Cited by 916
Bode, C., Zhao, G., Steinhagen, F., Kinjo, T., & Klinman, D. M. (2011) · Expert Review of Vaccines · doi:10.1586/erv.10.174 · Cited by 891
Miyamoto, K., Miyake, S., & Yamamura, T. (2001) · Nature · doi:10.1038/35097097 · Cited by 874
Carnaud, C., Lee, D., Donnars, O., Park, S.-H., Beavis, A., Koezuka, Y., & Bendelac, A. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.9.4647 · Cited by 854
Yoshimoto, T., & Paul, W. E. (1994) · The Journal of experimental medicine · doi:10.1084/jem.179.4.1285 · Cited by 841
Differential Tumor Surveillance by Natural Killer (Nk) and Nkt Cells
Smyth, M. J., Thia, K. Y. T., Street, S. E. A., Cretney, E., Trapani, J. A., Taniguchi, M., Kawano, T., Pelikan, S. B., Crowe, N. Y., & Godfrey, D. I. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.4.661 · Cited by 829
Recognition of Lipopeptide Patterns by Toll-like Receptor 2-Toll-like Receptor 6 Heterodimer
Kang, J. Y., Nan, X., Jin, M. S., Youn, S.-J., Ryu, Y. H., Mah, S., Han, S. H., Lee, H., Paik, S.-G., & Lee, J.-O. (2009) · Immunity · doi:10.1016/j.immuni.2009.09.018 · Cited by 765
Didierlaurent, A. M., Morel, S., Lockman, L., Giannini, S. L., Bisteau, M., Carlsen, H., Kielland, A., Vosters, O., Vanderheyde, N., Schiavetti, F., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901474 · Cited by 758
A Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Infants
The RTS, S. C. T. P. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1208394 · Cited by 752
Fujii, S.-I., Shimizu, K., Smith, C., Bonifaz, L., & Steinman, R. M. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030324 · Cited by 711
Davis, H. L., Weeranta, R., Waldschmidt, T. J., Tygrett, L., Schorr, J., & Krieg, A. M. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.2.870 · Cited by 677
Speiser, D. E., Líénard, D., Rufer, N., Rubio‐Godoy, V., Rimoldi, D., Lejeune, F. J., Krieg, A. Μ., Cerottini, J., & Romero, P. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200523373 · Cited by 640
CD1d–lipid-antigen recognition by the semi-invariant NKT T-cell receptor
Borg, N. A., Wun, K. S., Kjer-Nielsen, L., Wilce, M. C. J., Pellicci, D. G., Koh, R., Besra, G. S., Bharadwaj, M., Godfrey, D. I., McCluskey, J., et al. (2007) · Nature · doi:10.1038/nature05907 · Cited by 590
Bojang, K. A., Milligan, P. J., Pinder, M., Vigneron, L., Alloueche, A., Kester, K. E., Ballou, W. R., Conway, D. J., Reece, W. H., Gothard, P., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06957-4 · Cited by 528
Akahata, W., Yang, Z.-Y., Andersen, H., Sun, S., Holdaway, H. A., Kong, W.-P., Lewis, M. G., Higgs, S., Rossmann, M. G., Rao, S., et al. (2010) · Nature Medicine · doi:10.1038/nm.2105 · Cited by 515
Steinhagen, F., Kinjo, T., Bode, C., & Klinman, D. M. (2011) · Vaccine · doi:10.1016/j.vaccine.2010.08.002 · Cited by 501
GIANNINI, S., HANON, E., MORIS, P., VANMECHELEN, M., MOREL, S., DESSY, F., FOURNEAU, M., COLAU, B., SUZICH, J., & LOSONKSY, G. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.06.005 · Cited by 496
Molecular and cellular signatures of human vaccine adjuvants
Mosca, F., Tritto, E., Muzzi, A., Monaci, E., Bagnoli, F., Iavarone, C., O'Hagan, D., Rappuoli, R., & De Gregorio, E. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804699105 · Cited by 492
GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives
Garçon, N., Chomez, P., & Van Mechelen, M. (2007) · Expert Review of Vaccines · doi:10.1586/14760584.6.5.723 · Cited by 476
Morel, S., Didierlaurent, A., Bourguignon, P., Delhaye, S., Baras, B., Jacob, V., Planty, C., Elouahabi, A., Harvengt, P., & Carlsen, H. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.01.011 · Cited by 476
Viral evasion of intracellular DNA and RNA sensing
Chan, Y. K., & Gack, M. U. (2016) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2016.45 · Cited by 450
NK cells and NKT cells in innate defense against viral infections
Biron, C. A., & Brossay, L. (2001) · Current Opinion in Immunology · doi:10.1016/s0952-7915(00)00241-7 · Cited by 426
Fowlkes, B. J., Kruisbeek, A. M., Ton-That, H., Weston, M. A., Coligan, J. E., Schwartz, R. H., & Pardoll, D. M. (1987) · Nature · doi:10.1038/329251a0 · Cited by 397
Carbon nanotubes: a novel material for multifaceted applications in human healthcare
Kumar, S., Rani, R., Dilbaghi, N., Tankeshwar, K., & Kim, K.-H. (2017) · Chemical Society Reviews · doi:10.1039/c6cs00517a · Cited by 397
The crystal structure of human CD1d with and without α-galactosylceramide
Koch, M., Stronge, V. S., Shepherd, D., Gadola, S. D., Mathew, B., Ritter, G., Fersht, A. R., Besra, G. S., Schmidt, R. R., Jones, E. Y., et al. (2005) · Nature Immunology · doi:10.1038/ni1225 · Cited by 395
Recombinant vaccines and the development of new vaccine strategies
Nascimento, I. P., & Leite, L. C. C. (2012) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2012007500142 · Cited by 367
Comparative Safety of Vaccine Adjuvants: A Summary of Current Evidence and Future Needs
Petrovsky, N. (2015) · Drug Safety · doi:10.1007/s40264-015-0350-4 · Cited by 366
Type I Interferon-mediated Stimulation of T Cells by CpG DNA
Sun, S., Zhang, X., Tough, D. F., & Sprent, J. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.12.2335 · Cited by 361
Garçon, N., Vaughn, D. W., & Didierlaurent, A. M. (2012) · Expert Review of Vaccines · doi:10.1586/erv.11.192 · Cited by 347
Slingluff, C. L., Petroni, G. R., Yamshchikov, G. V., Barnd, D. L., Eastham, S., Galavotti, H., Patterson, J. W., Deacon, D. H., Hibbitts, S., Teates, D., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.005 · Cited by 322
Recent clinical experience with vaccines using MPL- and QS-21-containing Adjuvant Systems
Garçon, N., & Van Mechelen, M. (2011) · Expert Review of Vaccines · doi:10.1586/erv.11.29 · Cited by 314
Structure and function of a potent agonist for the semi-invariant natural killer T cell receptor
Zajonc, D. M., Cantu, C., Mattner, J., Zhou, D., Savage, P. B., Bendelac, A., Wilson, I. A., & Teyton, L. (2005) · Nature Immunology · doi:10.1038/ni1224 · Cited by 309
Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines
Aucouturier, J., Dupuis, L., Deville, S., Ascarateil, S., & Ganne, V (2002) · Expert Review of Vaccines · doi:10.1586/14760584.1.1.111 · Cited by 308
Unmet needs in modern vaccinology
Leroux-Roels, G. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.07.021 · Cited by 304
Valmori, D., Souleimanian, N. E., Tosello, V., Bhardwaj, N., Adams, S., O'Neill, D., Pavlick, A., Escalon, J. B., Cruz, C. M., Angiulli, A., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0703395104 · Cited by 299
Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity
Marciani, D. J. (2003) · Drug Discovery Today · doi:10.1016/s1359-6446(03)02864-2 · Cited by 290
Bianco, A., Hoebeke, J., Godefroy, S., Chaloin, O., Pantarotto, D., Briand, J.-P., Muller, S., Prato, M., & Partidos, C. D. (2005) · Journal of the American Chemical Society · doi:10.1021/ja044293y · Cited by 272
Self-citationDidierlaurent, A. M., Collignon, C., Bourguignon, P., Wouters, S., Fierens, K., Fochesato, M., Dendouga, N., Langlet, C., Malissen, B., Lambrecht, B. N., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1400948 · Cited by 266
McCluskie, M. J., & Davis, H. L. (1998) · PubMed · Cited by 264
Cho, H. J., Takabayashi, K., Cheng, P.-M., Nguyen, M.-D., Corr, M., Tuck, S., & Raz, E. (2000) · Nature Biotechnology · doi:10.1038/75365 · Cited by 258
Vellas, B., Black, R., Thal, L., Fox, N., Daniels, M., McLennan, G., Tompkins, C., Leibman, C., Pomfret, M., & Grundman, M. (2009) · Current Alzheimer Research · doi:10.2174/156720509787602852 · Cited by 255
de Titta, A., Ballester, M., Julier, Z., Nembrini, C., Jeanbart, L., van der Vlies, A. J., Swartz, M. A., & Hubbell, J. A. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1313152110 · Cited by 254
McCluskie, M. J., & Davis, H. L. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.9.4463 · Cited by 237
Knudsen, N. P. H., Olsen, A., Buonsanti, C., Follmann, F., Zhang, Y., Coler, R. N., Fox, C. B., Meinke, A., D´Oro, U., Casini, D., et al. (2016) · Scientific Reports · doi:10.1038/srep19570 · Cited by 235
Chiew Tong, N. K., Beran, J., Kee, S. A., Miguel, J. L., SanNchez, C., Bayas, J. M., Vilella, A., De Juanes, J. R., Arrazola, P., Calbo-Torrecillas, F., et al. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00689.x · Cited by 219
Vandepapelière, P., Horsmans, Y., Moris, P., Van Mechelen, M., Janssens, M., Koutsoukos, M., Van Belle, P., Clement, F., Hanon, E., Wettendorff, M., et al. (2008) · Vaccine · doi:10.1016/j.vaccine.2007.12.038 · Cited by 218
Calabro, S., Tritto, E., Pezzotti, A., Taccone, M., Muzzi, A., Bertholet, S., De Gregorio, E., O’Hagan, D. T., Baudner, B., & Seubert, A. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.05.007 · Cited by 214
Tandrup Schmidt, S., Foged, C., Smith Korsholm, K., Rades, T., & Christensen, D. (2016) · Pharmaceutics · doi:10.3390/pharmaceutics8010007 · Cited by 213
Toll‐like receptor 6‐independent signaling by diacylated lipopeptides
Buwitt‐Beckmann, U., Heine, H., Wiesmüller, K., Jung, G., Brock, R., Akira, S., & Ulmer, A. J. (2005) · European Journal of Immunology · doi:10.1002/eji.200424955 · Cited by 208
Natural and synthetic saponin adjuvant QS-21 for vaccines against cancer
Ragupathi, G., Gardner, J. R., Livingston, P. O., & Gin, D. Y. (2011) · Expert Review of Vaccines · doi:10.1586/erv.11.18 · Cited by 206
Novel adjuvants & delivery vehicles for vaccines development: a road ahead.
Mohan, T., Verma, P., & Rao, D. N. (2013) · Europe PMC (PubMed Central) · Cited by 199
Cooper, C. L., Davis, H. L., Angel, J. B., Morris, M. L., Elfer, S. M., Seguin, I., Krieg, A. M., & Cameron, D. W. (2005) · AIDS · doi:10.1097/01.aids.0000183514.37513.d2 · Cited by 191
Ko, S.-Y., Ko, H.-J., Chang, W.-S., Park, S.-H., Kweon, M.-N., & Kang, C.-Y. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.5.3309 · Cited by 182
Utilizing the adjuvant properties of CD1d-dependent NK T cells in T cell–mediated immunotherapy
Silk, J. D., Hermans, I. F., Gileadi, U., Chong, T. W., Shepherd, D., Salio, M., Mathew, B., Schmidt, R. R., Lunt, S. J., Williams, K. J., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200422046 · Cited by 174
Bessler, W. G., Cox, M., Lex, A., Suhr, B., Wiesmüller, K. H., & Jung, G. (1985) · The Journal of Immunology · doi:10.4049/jimmunol.135.3.1900 · Cited by 173
Carbohydrate vaccines as immunotherapy for cancer
Slovin, S. F., Keding, S. J., & Ragupathi, G. (2005) · Immunology & Cell Biology · doi:10.1111/j.1440-1711.2005.01350.x · Cited by 169
Antigenic mimicry of natural L-peptides with retro-inverso-peptidomimetics.
Guichard, G., Benkirane, N., Zeder-Lutz, G., van Regenmortel, M. H., Briand, J. P., & Muller, S. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.21.9765 · Cited by 162
Self-citationRecent trends in vaccine delivery systems: A review
Lakshmi, P., Bhaskaran, S., & Saroja, C. (2011) · International Journal of Pharmaceutical Investigation · doi:10.4103/2230-973x.82384 · Cited by 161
Virus-like particles for the prevention of human papillomavirus-associated malignancies
Wang, J. W., & Roden, R. B. S. (2013) · Expert Review of Vaccines · doi:10.1586/erv.12.151 · Cited by 157
Lin, A. Y., Almeida, J. P. M., Bear, A. S., Liu, N., Luo, L., Foster, A. E., & Drezek, R. A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063550 · Cited by 155
den Brok, M. H., Büll, C., Wassink, M., de Graaf, A. M., Wagenaars, J. A. L., Minderman, M., Thakur, M., Amigorena, S., Rijke, E., Schrier, C. C., et al. (2016) · Nature Communications · doi:10.1038/ncomms13324 · Cited by 147
The stimulating adventure of KRN 7000
Banchet, A., Hénon, É., Dauchez, M., Renault, J., Monneaux, F., & Haudrechy, A. (2011) · Organic & Biomolecular Chemistry · doi:10.1039/c0ob00975j · Cited by 144
CpG Oligonucleotides as Cancer Vaccine Adjuvants
Shirota, H., Tross, D., & Klinman, D. M. (2015) · Vaccines · doi:10.3390/vaccines3020390 · Cited by 138
Vaccine adjuvants – Current status and prospects on controlled release adjuvancity
Moni, S. S., Safhi, M. M., Kannadasan, M., & Sukumaran, N. (2011) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2011.06.003 · Cited by 132
Challenges in mucosal vaccines for the control of infectious diseases
Azegami, T., Yuki, Y., & Kiyono, H. (2014) · International Immunology · doi:10.1093/intimm/dxu063 · Cited by 131
The application of virus-like particles as vaccines and biological vehicles
Yan, D., Wei, Y., Guo, H., & Sun, S. (2015) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-015-7000-8 · Cited by 130
Jacobsen, N. E., Fairbrother, W. J., Kensil, C. R., Lim, A., Wheeler, D. A., & Powell, M. F. (1996) · Carbohydrate Research · doi:10.1016/0008-6215(95)00278-2 · Cited by 115
The Importance of Adjuvant Formulation in the Development of a Tuberculosis Vaccine
Baldwin, S. L., Bertholet, S., Reese, V. A., Ching, L. K., Reed, S. G., & Coler, R. N. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1102696 · Cited by 109
Mullen, G. E. D., Ellis, R. D., Miura, K., Malkin, E. M., Nolan, C., Hay, M., Fay, M. P., Saul, A. J., Zhu, D., Rausch, K. M., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002940 · Cited by 107
Eggermont, A. M. M., Suciu, S., Rutkowski, P. L., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.9303 · Cited by 107
Mucosal adjuvants and delivery systems for protein‐, DNA‐ and RNA‐based vaccines
Vajdy, M., Srivastava, I. K., Polo, J., Donnelly, J., O’Hagan, D. T., & Singh, M. (2004) · Immunology and Cell Biology · doi:10.1111/j.1440-1711.2004.01288.x · Cited by 105
Vaccine discovery and translation of new vaccine technology
Rappuoli, R., BLACK, S. B., & Lambert, P. H. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60440-6 · Cited by 105
Efficient Induction of Antitumor Immunity by Synthetic Toll-like Receptor Ligand–Peptide Conjugates
Zom, G. G., Khan, S., Britten, C. M., Sommandas, V., Camps, M. G. M., Loof, N. M., Budden, C. F., Meeuwenoord, N. J., Filippov, D. V., van der Marel, G. A., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0223 · Cited by 104
Schnurr, M. M., Orban, M., Robson, N. C., Shin, A., Braley, H., Airey, D., Cebon, J. S., Maraskovsky, E., & Endres, S. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.182.3.1253 · Cited by 100
Miles, A. P., McClellan, H., Rausch, K. M., Zhu, D., Whitmore, M. D., Singh, S. P., Martin, L. B., Wu, Y., Giersing, B. K., Stowers, A. W., et al. (2004) · Vaccine · doi:10.1016/j.vaccine.2004.08.049 · Cited by 99
Spohn, G., Jennings, G. T., Martina, B. E. E., Keller, I., Beck, M., Pumpens, P., Osterhaus, A. D. M. E., & Bachmann, M. F. (2010) · Virology Journal · doi:10.1186/1743-422x-7-146 · Cited by 99
Development of a minimal saponin vaccine adjuvant based on QS-21
Fernández‐Tejada, A., Chea, E. K., George, C. M., Pillarsetty, N., Gardner, J. R., Livingston, P. O., Ragupathi, G., Lewis, J. S., Tan, D. S., & Gin, D. Y. (2014) · Nature Chemistry · doi:10.1038/nchem.1963 · Cited by 98
The Council for Scientific and Industrial Research
(1959) · Nature · doi:10.1038/184780a0 · Cited by 86
Fogg, C. N., Americo, J. L., Lustig, S., Huggins, J. W., Smith, S. K., Damon, I. K., Resch, W., Earl, P. L., Klinman, D. M., & Moss, B. (2007) · Vaccine · doi:10.1016/j.vaccine.2006.12.037 · Cited by 85
Alpha-C-galactosylceramide as an adjuvant for a live attenuated influenza virus vaccine
Kopecky-Bromberg, S. A., Fraser, K. A., Pica, N., Carnero, E., Moran, T. M., Franck, R. W., Tsuji, M., & Palese, P. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.03.090 · Cited by 81
Jacobs, C., Duewell, P., Heckelsmiller, K., Wei, J., Bauernfeind, F. G., Ellermeier, J., Kisser, U., Bauer, C. A., Dauer, M., Eigler, A., et al. (2010) · International Journal of Cancer · doi:10.1002/ijc.25399 · Cited by 79
NKT cells: Potential targets for autoimmune disease therapy?
Hammond, K. J. L., & Godfrey, D. I. (2002) · Tissue Antigens · doi:10.1034/j.1399-0039.2002.590501.x · Cited by 76
MF59®‐adjuvanted vaccines for seasonal and pandemic influenza prophylaxis
Banzhoff, A., Pellegrini, M., Giudice, G. D., Fragapane, E., Groth, N., & Podda, A. (2008) · Influenza and Other Respiratory Viruses · doi:10.1111/j.1750-2659.2008.00059.x · Cited by 72
Thompson, A., & Thomas, R. (2002) · Immunology and Cell Biology · doi:10.1046/j.1440-1711.2002.01114.x · Cited by 64
Beck, Z., Matyas, G. R., & Alving, C. R. (2014) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2014.12.005 · Cited by 63
Kennedy, J. S., Co, M. D. T., Green, S., Longtine, K. J., Longtine, J., O'Neill, M. A., Adams, J. P., Rothman, A. L., Yu, Q., Johnson-Leva, R., et al. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.05.090 · Cited by 58
Borsutzky, S., Ebensen, T., Link, C., Becker, P. D., Valeria Fiorelli, A., Cafaro, A., Ensoli, B., & Guzmán, C. A. (2005) · Vaccine · doi:10.1016/j.vaccine.2005.11.025 · Cited by 55
Halliday, A., Turner, J. D., Guimaraes, A. F., Bates, P. A., & Taylor, M. J. (2016) · Parasites & Vectors · doi:10.1186/s13071-016-1381-0 · Cited by 54
Developing Antibacterial Vaccines in Genomics and Proteomics Era
Kaushik, D., & Sehgal, D. (2008) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.2008.02107.x · Cited by 52
Beignon, A., Briand, J., Muller, S., & Partidos, C. D. (2002) · Immunology · doi:10.1046/j.0019-2805.2001.01357.x · Cited by 51
Self-citationCheng, C., Jain, P., Bettahi, I., Pal, S., Tifrea, D. F., & de la Maza, L. M. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.06.105 · Cited by 51
Human prophylactic vaccine adjuvants and their determinant role in new vaccine formulations
Pérez, O., Batista-Duharte, A., González, E., Zayas, C., Balboa, J. A., Cuello, M., Cabrera, O., Lastre, M., & Schijns, V. E. C. J. (2012) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2012007500067 · Cited by 50
Peptide Vaccine Induces Enhanced Tumor Growth Associated with Apoptosis Induction in CD8+ T Cells
Muraoka, D., Kato, T., Wang, L., Maeda, Y., Noguchi, T., Harada, N., Takeda, K., Yagita∥, H., Guillaume, P., Luescher, I. F., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903649 · Cited by 50
Artiaga, B. L., Yang, G., Hackmann, T. J., Liu, Q., Richt, J. A., Salek‐Ardakani, S., Castleman, W. L., Lednicky, J. A., & Driver, J. P. (2016) · Scientific Reports · doi:10.1038/srep23593 · Cited by 46
Flow cytometric analysis of normal and reactive spleen
Colovai, A. I., Giatzikis, C., Ho, E. K., Farooqi, M., Suciu‐Foca, N., Cattoretti, G., & Orazi, A. (2004) · Modern Pathology · doi:10.1038/modpathol.3800141 · Cited by 45
Structure, mechanism and therapeutic utility of immunosuppressive oligonucleotides
Bayık, D., Gürsel, İ., & Klinman, D. M. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2015.11.010 · Cited by 39
Künzi, V., Klap, J. M., Seiberling, M., Herzog, C., Hartmann, K., Kürsteiner, O., Kompier, R., Grimaldi, R., & Goudsmit, J. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.03.062 · Cited by 37
Glycolipid ligands of invariant natural killer T cells as vaccine adjuvants
Kim, S., Lalani, S., Parekh, V. V., Wu, L., & Kaer, L. V. (2008) · Expert Review of Vaccines · doi:10.1586/14760584.7.10.1519 · Cited by 34
Nalla, N., Pallavi, P. M. C., Bonam, S. R., Miryala, S., Kumar, V. N., Mahboob, M., & Halmuthur, M. S. K. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.06.070 · Cited by 26
Self-citationFox, C. B., Huynh, C., O’Hara, M., & Onu, A. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.10.048 · Cited by 26
Use of nanoparticles to deliver immunomodulatory oligonucleotides
Klinman, D. M., Sato, T., & Shimosato, T. (2015) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1382 · Cited by 21
Stăvaru, C., Onu, A., Lupulescu, E., Ţucureanu, C., Raşid, O., Vlase, E., Coman, C., Caraș, I., Ghiorghisor, A., Berbecila, L., et al. (2015) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1111495 · Cited by 14
Down-regulation of IL-18 receptor in cancer patients: its clinical significance.
Kobashi, K., Iwagaki, H., Yoshino, T., Morimoto, Y., Kohka, H., Kodama, M., Nishibori, M., Akagi, T., & Tanaka, N. (2001) · PubMed · Cited by 8
Immunomodulatory consequences of ODN CpG-polycation complexes
Partidos, C. D., Hoebeke, J., Wieckowski, S., Chaloin, O., Bianco, A., Moreau, E., Briand, J., Des̀granges, C., & Muller, S. (2009) · Methods · doi:10.1016/j.ymeth.2009.03.005 · Cited by 8
Self-citation
Cited by
Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies
Patel, S. A., & Minn, A. J. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.007 · Cited by 573
Thi, T. T. H., Suys, E. J. A., Lee, J. S., Nguyen, D. H., Park, K. D., & Truong, N. P. (2021) · Vaccines · doi:10.3390/vaccines9040359 · Cited by 525
Optimizing the utilization of aluminum adjuvants in vaccines: you might just get what you want
HogenEsch, H., O’Hagan, D. T., & Fox, C. B. (2018) · npj Vaccines · doi:10.1038/s41541-018-0089-x · Cited by 391
Next-generation influenza vaccines: opportunities and challenges
Wei, C.-J., Crank, M. C., Shiver, J., Graham, B. S., Mascola, J. R., & Nabel, G. J. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0056-x · Cited by 332
Designing spatial and temporal control of vaccine responses
Roth, G. A., Picece, V. C. T. M., Ou, B. S., Luo, W., Pulendran, B., & Appel, E. A. (2021) · Nature Reviews Materials · doi:10.1038/s41578-021-00372-2 · Cited by 316
Metadata
- Authors
- Bonam, S. R., Partidos, C. D., Halmuthur, S. K. M., & Muller, S.
- Venue
- Trends in Pharmacological Sciences
- Publisher
- Elsevier BV
- Published
- 2017-09
- Volume
- 38
- Issue
- 9
- Pages
- 771-793
- ISSN
- 0165-6147 (ISSN-L)
- OpenAlex
- W2724154348
- Cited by
- 261
- References
- 115
- FWCI
- 1.82
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.